{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2019:BW6PNSPQKKLJTZDWFPLOVH4WEF","short_pith_number":"pith:BW6PNSPQ","canonical_record":{"source":{"id":"1907.05385","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2019-07-07T15:32:43Z","cross_cats_sorted":["stat.ME"],"title_canon_sha256":"bf7af96f5b4197bc5ee9a962649155919c3d1c1f6c20864d91f55ed5638fdc68","abstract_canon_sha256":"d9ac4ec71eebeb14d6e2f822c9e3a79299fd084ee001dbba9e93d4c414f20e7a"},"schema_version":"1.0"},"canonical_sha256":"0dbcf6c9f0529699e4762bd6ea9f962176d3550a0e8a5b24f045279b2ceb8200","source":{"kind":"arxiv","id":"1907.05385","version":1},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1907.05385","created_at":"2026-05-17T23:40:50Z"},{"alias_kind":"arxiv_version","alias_value":"1907.05385v1","created_at":"2026-05-17T23:40:50Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1907.05385","created_at":"2026-05-17T23:40:50Z"},{"alias_kind":"pith_short_12","alias_value":"BW6PNSPQKKLJ","created_at":"2026-05-18T12:33:12Z"},{"alias_kind":"pith_short_16","alias_value":"BW6PNSPQKKLJTZDW","created_at":"2026-05-18T12:33:12Z"},{"alias_kind":"pith_short_8","alias_value":"BW6PNSPQ","created_at":"2026-05-18T12:33:12Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2019:BW6PNSPQKKLJTZDWFPLOVH4WEF","target":"record","payload":{"canonical_record":{"source":{"id":"1907.05385","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2019-07-07T15:32:43Z","cross_cats_sorted":["stat.ME"],"title_canon_sha256":"bf7af96f5b4197bc5ee9a962649155919c3d1c1f6c20864d91f55ed5638fdc68","abstract_canon_sha256":"d9ac4ec71eebeb14d6e2f822c9e3a79299fd084ee001dbba9e93d4c414f20e7a"},"schema_version":"1.0"},"canonical_sha256":"0dbcf6c9f0529699e4762bd6ea9f962176d3550a0e8a5b24f045279b2ceb8200","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-17T23:40:50.464296Z","signature_b64":"dXfR4ToCp/TY2Tw8wvu10+TK8vPBpkMkFLeTvfm5TmOt0OTsd+SOf9BO+dZIX3rGwRy40YrJXS+TYgG8FlTHAg==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"0dbcf6c9f0529699e4762bd6ea9f962176d3550a0e8a5b24f045279b2ceb8200","last_reissued_at":"2026-05-17T23:40:50.463524Z","signature_status":"signed_v1","first_computed_at":"2026-05-17T23:40:50.463524Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"1907.05385","source_version":1,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-17T23:40:50Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"HvZacOZqJpJdXkifw6IMtyio8GDHtZKc9ROYQaqFjykNCpxEPFLe3OnF3+tNS+89fLMEfXB+4Y/5v48yP2aqAg==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-05-25T20:30:54.766874Z"},"content_sha256":"89ab8a0ce61e9e7cb48483d6a7bb0aa54b31f8e4fd5571ba34d1ae55527bc27d","schema_version":"1.0","event_id":"sha256:89ab8a0ce61e9e7cb48483d6a7bb0aa54b31f8e4fd5571ba34d1ae55527bc27d"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2019:BW6PNSPQKKLJTZDWFPLOVH4WEF","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Brand vs. Generic: Addressing Non-Adherence, Secular Trends, and Non-Overlap","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":["stat.ME"],"primary_cat":"stat.AP","authors_text":"Daniel O. Scharfstein, Irene B. Murimi, Jodi B. Segal, Lamar Hunt III, Marissa J. Seamans, Ravi Varadhan","submitted_at":"2019-07-07T15:32:43Z","abstract_excerpt":"While generic drugs offer a cost-effective alternative to brand name drugs, regulators need a method to assess therapeutic equivalence in a post market setting. We develop such a method in the context of assessing the therapeutic equivalence of immediate release (IM) venlafaxine, based on a large insurance claims dataset provided by OptumLabs\\textsuperscript{\\textregistered}. To properly address this question, our methodology must deal with issues of non-adherence, secular trends in health outcomes, and lack of treatment overlap due to sharp uptake of the generic once it becomes available. We "},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1907.05385","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-17T23:40:50Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"xXMoyDafS99PYlVrMctUMq9IWYLuk5/YWWa6kNvDP54G3tO6ngJ+MFnIMe0Zc+OG73Kax7fdDeEmElASY6+nAw==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-05-25T20:30:54.767311Z"},"content_sha256":"de5cd545c69e11b29e01ca25dd8881ed606c67d458eeb03930298fdecc288041","schema_version":"1.0","event_id":"sha256:de5cd545c69e11b29e01ca25dd8881ed606c67d458eeb03930298fdecc288041"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/BW6PNSPQKKLJTZDWFPLOVH4WEF/bundle.json","state_url":"https://pith.science/pith/BW6PNSPQKKLJTZDWFPLOVH4WEF/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/BW6PNSPQKKLJTZDWFPLOVH4WEF/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-05-25T20:30:54Z","links":{"resolver":"https://pith.science/pith/BW6PNSPQKKLJTZDWFPLOVH4WEF","bundle":"https://pith.science/pith/BW6PNSPQKKLJTZDWFPLOVH4WEF/bundle.json","state":"https://pith.science/pith/BW6PNSPQKKLJTZDWFPLOVH4WEF/state.json","well_known_bundle":"https://pith.science/.well-known/pith/BW6PNSPQKKLJTZDWFPLOVH4WEF/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2019:BW6PNSPQKKLJTZDWFPLOVH4WEF","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"d9ac4ec71eebeb14d6e2f822c9e3a79299fd084ee001dbba9e93d4c414f20e7a","cross_cats_sorted":["stat.ME"],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2019-07-07T15:32:43Z","title_canon_sha256":"bf7af96f5b4197bc5ee9a962649155919c3d1c1f6c20864d91f55ed5638fdc68"},"schema_version":"1.0","source":{"id":"1907.05385","kind":"arxiv","version":1}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1907.05385","created_at":"2026-05-17T23:40:50Z"},{"alias_kind":"arxiv_version","alias_value":"1907.05385v1","created_at":"2026-05-17T23:40:50Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1907.05385","created_at":"2026-05-17T23:40:50Z"},{"alias_kind":"pith_short_12","alias_value":"BW6PNSPQKKLJ","created_at":"2026-05-18T12:33:12Z"},{"alias_kind":"pith_short_16","alias_value":"BW6PNSPQKKLJTZDW","created_at":"2026-05-18T12:33:12Z"},{"alias_kind":"pith_short_8","alias_value":"BW6PNSPQ","created_at":"2026-05-18T12:33:12Z"}],"graph_snapshots":[{"event_id":"sha256:de5cd545c69e11b29e01ca25dd8881ed606c67d458eeb03930298fdecc288041","target":"graph","created_at":"2026-05-17T23:40:50Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"paper":{"abstract_excerpt":"While generic drugs offer a cost-effective alternative to brand name drugs, regulators need a method to assess therapeutic equivalence in a post market setting. We develop such a method in the context of assessing the therapeutic equivalence of immediate release (IM) venlafaxine, based on a large insurance claims dataset provided by OptumLabs\\textsuperscript{\\textregistered}. To properly address this question, our methodology must deal with issues of non-adherence, secular trends in health outcomes, and lack of treatment overlap due to sharp uptake of the generic once it becomes available. We ","authors_text":"Daniel O. Scharfstein, Irene B. Murimi, Jodi B. Segal, Lamar Hunt III, Marissa J. Seamans, Ravi Varadhan","cross_cats":["stat.ME"],"headline":"","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2019-07-07T15:32:43Z","title":"Brand vs. Generic: Addressing Non-Adherence, Secular Trends, and Non-Overlap"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1907.05385","kind":"arxiv","version":1},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:89ab8a0ce61e9e7cb48483d6a7bb0aa54b31f8e4fd5571ba34d1ae55527bc27d","target":"record","created_at":"2026-05-17T23:40:50Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"d9ac4ec71eebeb14d6e2f822c9e3a79299fd084ee001dbba9e93d4c414f20e7a","cross_cats_sorted":["stat.ME"],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2019-07-07T15:32:43Z","title_canon_sha256":"bf7af96f5b4197bc5ee9a962649155919c3d1c1f6c20864d91f55ed5638fdc68"},"schema_version":"1.0","source":{"id":"1907.05385","kind":"arxiv","version":1}},"canonical_sha256":"0dbcf6c9f0529699e4762bd6ea9f962176d3550a0e8a5b24f045279b2ceb8200","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"0dbcf6c9f0529699e4762bd6ea9f962176d3550a0e8a5b24f045279b2ceb8200","first_computed_at":"2026-05-17T23:40:50.463524Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-05-17T23:40:50.463524Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"dXfR4ToCp/TY2Tw8wvu10+TK8vPBpkMkFLeTvfm5TmOt0OTsd+SOf9BO+dZIX3rGwRy40YrJXS+TYgG8FlTHAg==","signature_status":"signed_v1","signed_at":"2026-05-17T23:40:50.464296Z","signed_message":"canonical_sha256_bytes"},"source_id":"1907.05385","source_kind":"arxiv","source_version":1}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:89ab8a0ce61e9e7cb48483d6a7bb0aa54b31f8e4fd5571ba34d1ae55527bc27d","sha256:de5cd545c69e11b29e01ca25dd8881ed606c67d458eeb03930298fdecc288041"],"state_sha256":"8083e7038baabf00d81d0b0a5ec8f522d61663022b90a780546e3b808af3beca"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"QpSfPWHu/Fd+A38FTS1lHbFmPCV7zek7pGo+LO+l84BWaqn3zSGZrHNHW76h+tghX6K+rWE3h5nBTNAMCwSpDg==","signed_message":"bundle_sha256_bytes","signed_at":"2026-05-25T20:30:54.770545Z","bundle_sha256":"a272d7681bfa580344d9c394ecddac5b9b63d2c6dac441a0b9cf860594b6309e"}}